id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2016-E-1888-0004,FDA,FDA-2016-E-1888,Letter from U.S. Patent and Trademark Office to FDA,Other,Letter(s),2016-12-27T05:00:00Z,2016,12,2016-12-27T05:00:00Z,,2016-12-27T18:01:50Z,,0,0,09000064824380f0
FDA-2016-E-1888-0003,FDA,FDA-2016-E-1888,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2016-08-26T04:00:00Z,2016,8,2016-08-26T04:00:00Z,,2016-08-26T13:26:19Z,,0,0,090000648219e752
FDA-2016-E-1888-0002,FDA,FDA-2016-E-1888,Letter from U.S. Patent and Trademark Office,Other,Letter(s),2016-07-05T04:00:00Z,2016,7,2016-07-05T04:00:00Z,,2016-07-05T18:10:16Z,,0,0,09000064820810e0
FDA-2016-E-1888-0001,FDA,FDA-2016-E-1888,Patent Extension Application from Nelson Mullins Riley & Scarborough LLP (on behalf Genmab A/S),Other,Application,2016-07-05T04:00:00Z,2016,7,2016-07-05T04:00:00Z,,2016-07-05T18:10:07Z,,0,0,09000064820810d8